

ASX Announcement

Change of Auditor

Perth, Australia; 2 October 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, “Orthocell” or the “Company”) advises that shareholders will be asked to approve the appointment of Deloitte Touche Tohmatsu as auditor of the Company at the Company’s Annual General Meeting to be held on 6 November 2026.

The proposed appointment follows the resignation of PKF Perth as auditor of the Company and the consent of the Australian Securities and Investments Commission (ASIC) to that resignation.

Deloitte has consented to act as auditor of Orthocell, subject to shareholder approval.

Chairman John Van Der Wielen said:

"On behalf of the Board, I would like to thank PKF Perth for its professionalism, expertise and support throughout its tenure as auditor of Orthocell."

Orthocell has evolved significantly in recent years and is entering an exciting phase of commercial growth, supported by expanding international operations and increasing corporate maturity. The Board believes Deloitte's experience supporting ASX-listed companies and global healthcare organisations will complement the Company's next phase of growth and further strengthen its governance and reporting framework.

We are pleased to recommend Deloitte's appointment to shareholders and look forward to working with the Deloitte team, subject to shareholder approval."

The Board unanimously recommends that shareholders vote in favour of the resolution to appoint Deloitte Touche Tohmatsu as auditor of the Company.

Release authorised by:

Paul Anderson

Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson

Orthocell Limited
CEO and MD

P: +61 8 9360 2888

E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres

H[^]CK Director

P: +61 423 139 163

E: haley@hck.digital

Investor enquiries

Shaun Duffy

VECTOR Advisors

P: +61 404 094 384

E: sduffy@vectoradvisors.au



About Orthocell Limited

ACN 118 897 135

Registered Office – Level 2, 161 Campus Drive, Murdoch University, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.